EyePoint Pharmaceuticals Sets Pricing of Its Public Stock Offering
Published on October 16, 2025
WATERTOWN, Mass.—EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a clinical-stage biopharmaceutical company and a developer of therapeutics for patients with serious retinal diseases, announced it has priced an underwritten public offering of 11 million shares of common stock at $12.00 per share and pre-funded warrants to purchase up to 1.5 million additional shares. The offering is expected to generate approximately $150 million in gross proceeds before underwriting discounts and other expenses, and the transaction is scheduled to close on or about October 16, 2025, subject to the satisfaction of customary closing conditions, the announcement noted.